Eli Lilly and Company (MARCS-CMS 716462)
FDA has issued 3 warning letters to Eli Lilly and Company:
- September 9, 2025: ZEPBOUND (tirzepatide) Injection, for subcutaneous use (NDA 217806) (this letter)
Letter facts
- Letter date
- September 9, 2025 (2025-09-09)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Products named
- ZEPBOUND (tirzepatide) Injection, for subcutaneous use (NDA 217806)
- Violation categories
- MisbrandingFalse or misleading claims
Understanding these violation categories
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
False or misleading claims
FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.
Factual Violation Summary
FDA says a sponsored online video promoting Zepbound omitted all risk information and the drug's limitations of use, creating a misleading impression of safety and approved use, and was not submitted to FDA under Form FDA-2253 when initially published.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- false or misleading promotional communication (misbranding)
- omission of risk information
- omission of material facts (limitations of use)
- failure to submit under Form FDA-2253 at time of initial publication
More letters about Tirzepatide
Recent FDA warning letters concerning Tirzepatide:
- RonanRxOctober 30, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
Similar violations (Misbranding)
Recent warning letters with related regulatory findings:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.